Kyverna Therapeutics share price logo

Kyverna Therapeutics Share Price

NASDAQ: KYTX

Small Cap

$4.38

+0.51

(+13.18%)

as on

Kyverna Therapeutics Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $3.98
    $4.44
    downward going graph

    9.13%

    Downside

    1.37%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.78
    $7.35
    downward going graph

    59.36%

    Downside

    67.81%

    Upside

    downward going graph

Kyverna Therapeutics share price movements today

Previous Close
$3.87
Open
$4.00
Volume
754.5K
Day's Low - High
$3.98 - $4.44
52 Week Low - High
$1.78 - $7.35

Kyverna Therapeutics Historical Returns

1 Month Return
+ 11.4 %
3 Month Return
+ 32.09 %
1 Year Return
-41.29 %
3 Year Return
0 %
5 Year Return
0 %

Kyverna Therapeutics Stock Fundamentals & Key Indicators

Check Kyverna Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$169.1M

EPS (TTM)

-3.8084

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-170.4M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

2523000.00%

Kyverna Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyverna Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$169.1MNANA0.00%
BUY$60.5B252.04%-505.15-12.96%
NA$39.0BNANA-3.89%
BUY$100.3B44.17%27.8531.86%
BUY$59.6B1.78%14.131.37%

Stock Returns calculator for Kyverna Therapeutics Stock including INR - Dollar returns

The Kyverna Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Kyverna Therapeutics investment value today

Current value as on today

₹70,364

Returns

₹29,636

(-29.64%)

Returns from Kyverna Therapeutics Stock

₹34,234 (-34.23%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Kyverna Therapeutics Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Kyverna Therapeutics. Average target price of $18.2

Kyverna Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Kyverna Therapeutics.

What analysts predicted

75.93%UPSIDE

Target Price

$18.2

Current Price

$4.38

Analyzed by

10 Analysts

Target

$18.20

Kyverna Therapeutics target price $18.2, a slight upside of 75.93% compared to current price of $4.38. According to 10 analysts rating.

Kyverna Therapeutics Stock's Interest Amongst Investors

Search interest for Kyverna Therapeutics Stock has decreased by -64% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-64% versus previous 30 day period

Kyverna Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
-
2
-
-
Gross Profit
-8
0
0
0
0
0
0
0
0
0
Operating Income
-11
-13
-16
-21
-29
-33
-38
-41
-47
-44
EBITDA
-10
-12
-14
-20
-26
-28
-33
-36
-47
-44
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-13
-15
-20
-26
-28
-34
-37
-44
-42
Income Tax Expense
0
-
-
0
0
-
-
-
-
-
Net Income
-11
-13
-15
-20
-26
-28
-34
-37
-44
-42
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-1852.22%
0.00%
0.00%

Kyverna Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
5
7
-
-
Gross Profit
5
5
-1
-2
Operating Income
-26
-29
-62
-142
EBITDA
-25
-27
-58
-125
Interest Expense
0
0
0
0
Depreciation
0
1
1
2
Income Before Tax
-26
-28
-60
-127
Income Tax Expense
0
0
0
-127
Net Income
-26
-28
-60
-127
Net Profit Margin
-465.88%
-411.29%
0.00%
0.00%

Kyverna Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-13
-15
-20
-26
-28
-34
-37
-44
-42
Operating Cash Flow
-11
-11
-18
-25
-24
-27
-37
-44
-31
Investing Cash Flow
0
-54
31
-122
-67
0
29
5
29
Financing Cash Flow
24
34
-1
338
0
0
0
0
0
Change in Cash
13
-30
11
189
-92
-26
-8
-39
-3

Kyverna Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Net Income
-28
-60
-127
Operating Cash Flow
-36
-52
-114
Investing Cash Flow
-14
-8
-160
Financing Cash Flow
11
58
337
Change in Cash
-38
-3
61

Insights on Kyverna Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 110.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, KYTX stock has moved down by -3.7%

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
OrganisationKyverna Therapeutics
Headquarters5980 Horton Street, EmeryVille, CA, United States, 94608
CEOMr. Warner Biddle
E-voting on sharesClick here to vote

Key Management of Kyverna Therapeutics

Name

Title

Dr. Tom Van Blarcom Ph.D.

Senior VP & Head of Research

Mr. Dan Maziasz

Chief Business Officer

Dr. Naji H. Gehchan M.B.A., M.D.

Chief Medical & Development Officer

Dr. Marc Grasso M.D.

Chief Financial Officer

Ms. Karen Walker

Chief Technology Officer

Ms. Tracy Rossin

Senior Vice President of Corporate Affairs & Communications and Investor Relations

Ms. Cara Bauer Ph.D.

Chief Human Resources Officer

Dr. Sham Dholakia DPHIL, M.D.

Chief Product Officer

Mr. Warner Biddle

CEO & Director

FAQs

What is Kyverna Therapeutics share price today?

Kyverna Therapeutics share price today is $4.38 as on at the close of the market. Kyverna Therapeutics share today touched a day high of $4.44 and a low of $3.98.

What is the 52 week high and 52 week low for Kyverna Therapeutics share?

Kyverna Therapeutics share touched a 52 week high of $7.35 on and a 52 week low of $1.78 on . Kyverna Therapeutics stock price today i.e. is closed at $4.38,which is 40.41% down from its 52 week high and 146.07% up from its 52 week low.

What is Kyverna Therapeutics's market capitalisation today?

Kyverna Therapeutics market capitalisation is $0.00T as on .

How to invest in Kyverna Therapeutics Stock (KYTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kyverna Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyverna Therapeutics Shares that will get you 0.3425 shares as per Kyverna Therapeutics share price of $4.38 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Kyverna Therapeutics Stock (KYTX) from India?

Indian investors can start investing in Kyverna Therapeutics (KYTX) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Kyverna Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Kyverna Therapeutics share’s latest price of $4.38 as on September 18, 2025 at 1:29 am IST, you will get 2.2831 shares of Kyverna Therapeutics. Learn more about fractional shares .